Oncology Pharmacy Specialty Review Course for Recertification + RECERT EXAM (Cert # L209089)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 04/15/2020
Content Release Date: 04/29/2020
Expiration Date: 04/13/2021
Activity Type: Application-based
CE Credits: 25.75 (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were recorded during a live educational event on March 5-7, 2020, at the ACCP/ASHP’s 2020 Live Review & Recert Courses, Henderson, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in oncology pharmacy.

Activity Overview

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study 

This online course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 25.75 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

Learning Module

ACPE Number

Credit Hours

Assessment Pass Point

Oncology Pharmacy Specialty Review and Recertification Course: Breast Cancer

0204-9999-20-922-H01-P

2.50

72%

Oncology Pharmacy Specialty Review and Recertification Course: Gynecologic Malignancies

0204-9999-20-914-H01-P

1.00

Oncology Pharmacy Specialty Review and Recertification Course: Prostate Cancer

0204-9999-20-916-H01-P

1.00

Oncology Pharmacy Specialty Review and Recertification Course: Pediatric Malignancies and Supportive Care

0204-9999-20-926-H01-P

1.25

Group 1 Assessment 

5.75

Oncology Pharmacy Specialty Review and Recertification Course: Upper Gastrointestinal and Hepatocellular Carcinomas

0204-9999-20-924-H01-P

0.75

76%

Oncology Pharmacy Specialty Review and Recertification Course: Bladder, Renal Cell, and Testicular Cancers

0204-9999-20-929-H01-P

1.00

Oncology Pharmacy Specialty Review and Recertification Course: Melanoma and Non-Melanoma Skin Cancers

0204-9999-20-915-H01-P

1.00

Oncology Pharmacy Specialty Review and Recertification Course: Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-20-912-H04-P

2.00

Group 2 Assessment 

4.75

Oncology Pharmacy Specialty Review and Recertification Course: Adult Acute Leukemias and Myelodysplastic Syndromes

0204-9999-20-928-H01-P

1.50

83%

Oncology Pharmacy Specialty Review and Recertification Course: Lymphomas

0204-9999-20-925-H01-P

1.25

Oncology Pharmacy Specialty Review and Recertification Course: Chronic Leukemias

0204-9999-20-917-H01-P

1.50

Oncology Pharmacy Specialty Review and Recertification Course: Hematopoietic Stem Cell Transplantation

0204-9999-20-921-H01-P

1.25

Group 3 Assessment 

5.50

Oncology Pharmacy Specialty Review and Recertification Course: Lung Cancer

0204-9999-20-923-H01-P

1.50

72%

Oncology Pharmacy Specialty Review and Recertification Course: Lower Gastrointestinal and Pancreatic Cancers

0204-9999-20-927-H01-P

1.25

Oncology Pharmacy Specialty Review and Recertification Course: Head, Neck and Adult Central Nervous System (CNS) Malignancies

0204-9999-20-930-H01-P

1.00

Oncology Pharmacy Specialty Review and Recertification Course: Cancer-related Infectious Diseases

0204-9999-20-931-H01-P

1.00

Group 4 Assessment 

4.75

Oncology Pharmacy Specialty Review and Recertification Course: Oncology Practice Management

0204-9999-20-920-H04-P

2.00

77%

Oncology Pharmacy Specialty Review and Recertification Course: Multiple Myeloma

0204-9999-20-918-H01-P

1.50

Oncology Pharmacy Specialty Review and Recertification Course: Adult Sarcoma

0204-9999-20-919-H01-P

0.75

Oncology Pharmacy Specialty Review and Recertification Course: Pharmacogenomics in Oncology

0204-9999-20-913-H01-P

0.75

Group 5 Assessment 

5.00

Learning Objectives

At the end of the presentations, the pharmacist should be able to:

Breast Cancer

ACPE #: 0204-9999-20-922-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on  genomic test results
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).
Gynecologic Malignancies

ACPE #: 0204-9999-20-914-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient a with a gynecologic malignancy.
  • Discuss short- and long-term goals including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver
  • Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening) for gynecologic malignancies.
Prostate Cancer

ACPE #: 0204-9999-20-916-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Identify appropriate diagnostic, prognostic, and monitoring tests for a patient with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).
Pediatric Malignancies and Supportive Care

ACPE #: 0204-9999-20-926-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
  • Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

ACPE #: 0204-9999-20-924-H01-P

  •  Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Develop appropriate plans for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

ACPE #: 0204-9999-20-929-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinoma.
  • Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinoma and his or her caregiver.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.

ACPE #: 0204-9999-20-915-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with melanoma skin cancer.
  • Discuss short-term and long-term treatment goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

ACPE #: 0204-9999-20-912-H04-P

  • Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
  • Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study

ACPE #: 0204-9999-20-928-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.

ACPE #: 0204-9999-20-925-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

ACPE #: 0204-9999-20-917-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic leukemia.
  • Determine appropriate pharmacotherapy based on  genomic test results in a patient with chronic leukemia.
  • Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

ACPE #: 0204-9999-20-921-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
  • Apply appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens, and differentiate between myeloablative, non‐myeloablative, and reduced-intensity HSCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies. 
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

ACPE #: 0204-9999-20-923-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
  • Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.

ACPE #: 0204-9999-20-927-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

ACPE #: 0204-9999-20-930-H01-P

  • Design an appropriate patient-specific treatment, management and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS) malignancies, or thyroid cancers.
  • Select relevant information and guidance to the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, and screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.

ACPE #: 0204-9999-20-931-H01-P

  • Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
  • Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

ACPE #: 0204-9999-20-920-H04-P

  • Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

ACPE #: 0204-9999-20-918-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression in all oncology patients.

ACPE #: 0204-9999-20-919-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  •  Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

ACPE #: 0204-9999-20-913-H01-P

  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
  • Apply the results from somatic genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapeutic decision making for companion diagnostic testing.

Planners, Presenters and Reviewers

Jessica Auten, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
UNC Medical Center
Chapel Hill, North Carolina
Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 
Karen M. Fancher, Pharm.D., BCOP*
Assistant Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist
Passavant Hospital - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania 
Christopher A. Fausel, Pharm.D., MHA, BCOP
Clinical Manager - Oncology Pharmacy
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana
Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Lauren Ice, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan
Steven Ludlow, Pharm.D., BCOP, BCPS
Medical Oncology Clinical Pharmacy Specialist
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Elyse A. MacDonald, Pharm.D., M.S., BCPS
Pharmacy Manager, Investigational Drug Service
University of Utah Health
Salt Lake City, Utah
Janelle Mann, Pharm.D., BCOP
Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center
Clinical Oncology Pharmacist
Washington University School of Medicine
St. Louis, Missouri
Clinical Pharmacist Specialist - Inpatient Hematology
Adjunct Clinical Assistant Professor
University of Michigan Health System
Ann Arbor, Michigan 
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, NY
Danielle Roman, Pharm.D., BCOP*
Manager - Clinical Pharmacy Services
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
Christine M. Walko, Pharm.D., BCOP*
Personalized Medicine Specialist
H. Lee Moffitt Cancer Center
DeBartolo Family Personalized Medicine Institute
Associate Professor - Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida 
Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

*Content Matter Experts

Angela T. Cassano, Pharm.D., BCPS, FASHP
Susan R. Dombrowski, M.S., R.Ph.
Courtney Alexander, Pharm.D., BCPS, BCOP
Laura Bobolts, Pharm.D., BCOP
Joseph Bubalo, Pharm.D., BCOP, BCPS
Ryan Bycroft, Pharm.D., BCOP
Nicholas Chow, Pharm.D.,BCOP
Jill Comeau, Pharm.D., BCOP
Brette Conliffe, Pharm.D.
Erik De Freitas, Pharm.D., MPH, MNSSS, BCOP
Bryna Delman Ewachiw, Pharm.D., BCOP
Amber Draper, Pharm.D., BCOP
Sean Green, Pharm.D., BCOP
Hansen Ho, Pharm.D., BCOP
Sarah Hoffman, Pharm.D., BCOP
Christine Hong, Pharm.D., BCOP
Shannon Hough, Pharm.D., BCOP
Caren Hughes, Pharm.D., BCOP, MBA
Mitchell  Hughes, Pharm.D., BCPS, BCOP
Anna Jan, Pharm.D., BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Jeff Kaiser, Pharm.D., BCOP, BCPS
Minhee Kang, Pharm.D., BCOP, BCPS
Lindsay Kaster, Pharm.D., BCOP
Jennifer Kerns, Pharm.D., BCOP
Michael Leung, Pharm.D., BCOP
Suwicha Limvorasak, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Benjamin Moskoff, Pharm.D., BCOP
Heather Pound, Pharm.D., BCPS, BCOP
David Reeves, Pharm.D., BCOP
Melvin Rivera, Pharm.D., BCOP
Glenn Roma, Pharm.D., Ph.D., BCOP
Katherine Saunders, Pharm.D., BCOP
Gianni Scappaticci, Pharm.D., BCOP
Danielle Schlafer, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Jigar Trivedi, M.S., Pharm.D., BCOP
Cory Vela, Pharm.D., BCOP
Kristin Wheatley, Pharm.D., BCOP
Katie Won, Pharm.D., BCOP
Rebecca Young, Pharm.D., BCOP
Mark Zangardi, Pharm.D., BCOP

Courtney Alexander, Pharm.D., BCPS, BCOP
Robert Appell, Pharm.D., BCOP
Laura Bobolts, Pharm.D., BCOP
Joseph Bubalo, Pharm.D., BCPS, BCOP
Margaret Bush, BS Pharm, Ph.D., BCOP
Ryan Bycroft, Pharm.D., BCOP
Christopher Campbell, Pharm.D., BCPS, BCOP
Eunah Cho, Pharm.D., BCOP
Nicholas Chow, Pharm.D., BCOP
Jill Comeau, Pharm.D., BCOP
Brette Conliffe, Pharm.D., BCOP
Erik De Freitas, Pharm.D., BCOP, MPH
Amber Draper, Pharm.D., BCOP
Linda Elnazir, Pharm.D., BCPS, BCOP
Bryna Ewachiw, Pharm.D.,BCOP
Bradi Frei, Pharm.D., BCPS, BCOP
Alicia Gesenhues, Pharm.D., BCOP
Emily Graham, Pharm.D., MS, BCOP
Sean Green, Pharm.D., BCOP
Hansen Ho, Pharm.D,. BCOP
Sarah Hoffman, Pharm.D., BCOP
Christine Hong, Pharm.D., BCOP
Shannon Hough , Pharm.D., BCOP
Caren Hughes, Pharm.D., BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Anna Jan, Pharm.D., BCOP
Austin Jenkins, Pharm.D., BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Angela Johnston Willis, Pharm.D., BCPS, BCOP
Jocelyn Joseph, Pharm.D., BCOP
Jeff Kaiser, Pharm.D., BCPS, BCOP
Minhee Kang, Pharm.D., BCOP, BCPS
Shraddha Kansagra, Pharm.D., BCOP
Lindsay Kaster, Pharm.D., BCOP
Jennifer Kerns, Pharm.D., BCOP
Carly Kesler, Pharm.D., BCOP
Michael Leung, Pharm.D., BCOP
Whitney Lewis, Pharm.D., BCOP
Suwicha Limvorasak, Pharm.D., BCOP
Valerie Lindeborg, Pharm D., BCOP, BCSCP
Robin Lockhorst, Pharm.D.
Samantha Luk , Pharm.D., BCOP
Robert Luschen, Pharm.D., BCOP
Margaret McGuinness, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Kesha Morgan, Pharm.D., BCPS, BCOP
Benjamin Moskoff, Pharm.D. BCOP
David Nowinski, Pharm.D., BCOP
Chukwuemeka Nzelibe , Pharm.D., BCOP, MBA
Nabil Omar, Pharm.D., BCOP
Kara Osborne, Pharm.D., BCOP
Carol Peek, Pharm.D., BCOP
Laura Poggi, Pharm.D., BCOP
Heather Pound, Pharm.D., BCPS, BCOP
Heena Rathod, Pharm.D., BCOP
Mohammad Rattu, Pharm.D., BCOP, BCPS, BCGP
David Reeves, Pharm.D., BCOP
Amy Riedel, Pharm.D., BCPS, BCOP
Melvin Rivera, Pharm.D., BCOP
Glenn Roma, Pharm.D., Ph.D., BCOP
Kristen Rychalsky, Pharm.D., BCPS, BCOP
Stephanie Sanders, Pharm.D., BCOP
Katherine Saunders, Pharm.D., BCOP
Gianni Scappaticci, Pharm.D., BCOP
Hope Schenk, Pharm.D., BCOP
Danielle Schlafer, Pharm.D., BCOP
Brian Seiki, Pharm.D., BCOP
Meenakshi Shelat, Pharm.D., BCOP
Sunao Slayton, Pharm.D., BCOP
Cynthia Spencer, BS Pharm, BCOP
Anne Spengler, Pharm.D., BCOP
Matthew St.Amand, Pharm.D., BCOP
Lindsay Stansfield, Pharm.D., BCPS, BCOP
Chipman Stroud, Pharm.D., BCOP
Minal Surati, Pharm.D., BCOP
Chia Jie Tan, BPharm(Hons), BCOP
Christan Thomas, Pharm.D., BCOP
Ajoke Tijani, Pharm.D.., BCOP
Jigar Trivedi, MS, Pharm.D., BCOP
Jessica Unzaga, Pharm.D., BCPS, BCOP
Cory Vela, Pharm.D., BCOP
Alma Villescas, R.Ph., BCOP
Sheng Fan Wang, Ph.D., BCOP
Kristin Wheatley, Pharm.D., BCOP
Eryn Whitaker, Pharm.D., BCOP, APh
Katie Won, Pharm.D., BCOP
Vincent WONG, MPharm, BCGP, BCPS, BCOP
Chen Xu, Ph.D., BCOP
Lily Yan, Pharm.D., BCOP
Rebecca Young, Pharm.D., BCOP
Mark Zangardi, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen M. Fancher, Pharm.D., BCOP: Consultant, AstraZeneca, LP
  • Anthony J. Perissinotti, Pharm.D., BCOP: Consultant, Servier
  • Christine M. Walko, Pharm.D., BCOP, FCCP: Consultant, Foundation Medicine; MTB Consultant, Jackson Genetic Laboratories; MTB Consultant, Intermountain Healthcare
  • All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development

These activities were developed by ASHP and ACCP.